An Introduction to Huntington’s Disease
Huntington’s Disease (HD) is a rare, incurable, inherited and ultimately fatal neurodegenerative disorder characterised by chorea, ataxia, dysphagia, cognitive and behavioural changes. Current therapies offer only symptomatic relief, and many are associated with significant side effects, though pridopidine, a sigma-1-receptor (S1R) agonist has shown potential for both symptomatic treatment and disease modifying effects in HD. Advances in our understanding of the pathogenesis of HD have highlighted the importance of DNA repair genes, and novel approaches, such as the antisense therapy tominersen and the oral agent branaplam, are targeting the mutant huntingtin (mHTT) protein and the HTT gene. However, no disease-modifying therapy is yet approved for HD.
Our supporting partners do not constitute an endorsement of the content on this page.
Huntington’s Disease Content
Rebecca Gilbert AAN, 2021: Update on Clinical Trials in Parkinson’s and Huntington’s Diseases
We were pleased to meet with one of our valued Editorial Board Members, Rebecca Gilbert, MD, PhD (American Parkinson Disease Association, Staten Island, NY, USA) to discuss highlights from the AAN session entitled ‘Update on Clinical Trials in Parkinson’s and Huntington’s Diseases’ presented at the American Academy of Neurology Virtual Annual Meeting 2021. Questions: In […]
Andrew Feigin and Ralf Reilmann, AD/PD 2021: The PROOF-HD Study
touchNEUROLOGY had the pleasure of meeting with Andrew Feigin (Department of Neurology, NYU Grossman School of Medicine, New York City, NY, USA) and Ralf Reilmann (Founding Director, George Huntington Institute, Münster, Germany), to discuss the clinical utility of pridopidine in Huntington’s disease, and the ongoing PROOF-HD study. The abstract entitled ‘The PROOF-HD Study: Pridopidine’s Outcome […]
Andrew Feigin, AD/PD 2021: Results from the Phase 2 SIGNAL Trial
We had the opportunity to meet with Andrew Feigin (Department of Neurology, NYU Grossman School of Medicine, New York City, NY, USA) to discuss the results from the phase 2 Huntington’s Disease trial of Anti-Semaphorin 4D Antibody Pepinemab (SIGNAL). The abstract entitled ‘Results of Phase 2 Huntington’s Disease Trial of Anti-Semaphorin 4D Antibody Pepinemab (SIGNAL) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!